Axillary Management after Neoadjuvant Endocrine Therapy (NET).

ABSTRACT:

Background

In patients with hormone receptor-positive (HR⁺), HER2-negative breast cancer, there is a lack of data available to define optimal axillary management strategies after neoadjuvant endocrine therapy (NET).

Patients and methods

We performed a retrospective review of patients with clinical stage I-III, HR⁺ breast cancer who received > 90 days of NET at a single comprehensive cancer center between 2004 and 2024.

Results

A total of 230 patients were included; 120 (52.2%) were clinically node-negative (cN0), while 110 (47.8%) were clinically node-positive (cN+). In the cN+ group, 7.3% (8/110) had a nodal pathologic complete response (pCR). In total, 76.4% (84/110) in the cN+ group underwent axillary lymph node dissection (ALND) as the initia

SUBMITTER: Leonard L 

PROVIDER: S-EPMC12866965 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature